User profiles for Jonathan S Nguyen-Van-Tam
 | Jonathan Van TamProfessor of Health Protection, University of Nottingham Verified email at nottingham.ac.uk Cited by 25076 |
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Objective To characterise the clinical features of patients admitted to hospital with coronavirus
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
…, C Charman, P Mande, JS Nguyen-Van-Tam… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has caused hundreds of millions of cases and continues to circulate globally. To establish …
has caused hundreds of millions of cases and continues to circulate globally. To establish …
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C …
Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, PJ Turner, LL Walker, R White, JS Nguyen-Van-Tam… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic …
…, JS Nguyen-Van-Tam… - The Journal of …, 2015 - academic.oup.com
Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin
may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of …
may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of …
Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study
…, L Sigfrid, IP Sinha, PL Olliaro, JS Nguyen-Van-Tam… - bmj, 2020 - bmj.com
Objective To characterise the clinical features of children and young people admitted to
hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
…, S Khoo, S Petrou, K Hood, JS Nguyen-Van-Tam… - The Lancet, 2023 - thelancet.com
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum
According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
Objectives To derive and validate risk prediction algorithms to estimate the risk of covid-19
related mortality and hospital admission in UK adults after one or two doses of covid-19 …
related mortality and hospital admission in UK adults after one or two doses of covid-19 …